Immunomodulatory Effect of the Bacillus Calmette–Guérin (BCG) Vaccine on the In Vitro Interferon Response Induced by Respiratory Syncytial Virus (RSV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antigens
18. März 2025
Über diesen Artikel
Artikel-Kategorie: Original
Online veröffentlicht: 18. März 2025
Eingereicht: 21. Okt. 2024
Akzeptiert: 29. Jan. 2025
DOI: https://doi.org/10.2478/aite-2025-0007
Schlüsselwörter
© 2025 Magdalena Jurczak et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Fig 1.

Fig 2.

Fig 3.

Fig 4.

The characteristics of the groups of the study
Parameter | Groups | |||
---|---|---|---|---|
RSV(+) | SARS-CoV-2(+) | RSV(+) SARS-CoV-2(+) | RSV(−) SARS-CoV-2 (−) | |
14 | 17 | 11 | 6 | |
Sex M/F | 6/8 | 12/5 | 5/6 | 2/4 |
Ethnicity | Caucasian | Caucasian | Caucasian | Caucasian |
Age median | 9 | 9 | 8 | 8 |
Age range | 7–12 | 6–12 | 7–12 | 7–12 |
BCG vaccination | 100% | 100% | 100% | 100% |
Leukocytes (tys/μL) | 8.27 | 7.55 | 8.64 | 9.42 |
Erythrocytes (mln/μL) | 4.75 | 4.83 | 4.81 | 5.26 |
Hemoglobin (g/dL) | 13.29 | 12.76 | 13.52 | 13.43 |
Hematocrit (%) | 39.00 | 38.93 | 39.50 | 39.15 |
MCV (fl) | 82.21 | 77.76 | 82.36 | 74.50 |
MCH (pg) | 28.00 | 28.04 | 28.18 | 25.50 |
MCHC (g/dL) | 34.06 | 50.62 | 34.21 | 34.17 |
Platelets (tys/μL) | 306.29 | 304.71 | 333.18 | 424.83 |
RDW-SD (fl) | 38.82 | 36.04 | 38.90 | 37.02 |
RDW-CV (%) | 13.16 | 12.18 | 13.15 | 14.03 |
PDW (fl) | 11.57 | 12.46 | 11.41 | 10.22 |
MPV (fl) | 10.06 | 10.15 | 10.04 | 9.25 |
P-LCR (%) | 25.64 | 25.98 | 25.47 | 19.40 |
PCT (%) | 0.34 | 0.32 | 0.35 | 0.40 |
Neutrophils (%) | 49.23 | 45.74 | 51.69 | 52.48 |
Lymphocytes (%) | 35.66 | 35.96 | 34.43 | 33.68 |
Monocytes (%) | 9.45 | 8.63 | 8.65 | 6.82 |
Eosinophils (%) | 5.18 | 7.79 | 4.75 | 5.30 |
Basophils (%) | 0.36 | 0.55 | 0.35 | 0.58 |